|
i3 Health |
Share:
|
Overviewi3 Health's mission is to enhance the proficiency of the multidisciplinary health care team by providing evidence-based, fair-balanced CME/NCPD/CPE activities that address identified professional practice gaps and unmet educational needs. We partner with key opinion leaders, academic/research institutions, professional societies, peer-reviewed journals, and social media platforms to develop and deliver the most innovative educational programming in health care. |
Comprehensive Management of Von Hippel-Lindau Disease: Genetic and Oncological Perspectives
STATEMENT OF NEED
Von Hippel-Lindau disease (VHL) is an autosomal dominant disease in which germline pathogenic variants in the VHL gene predispose individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, including clear cell renal cell carcinoma (RCC), renal cysts, central nervous system hemangioblastomas, retinal hemangioblastomas, pancreatic tumors and ...
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous ...
|
|
Management of Cancer Pain: Current Guidelines
STATEMENT OF NEED
Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-seve...
|
|
Management of Venous Thromboembolism in Ambulatory Patients With Cancer
STATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer. The risk of cancer-related VTE has risen in the past 2 decades, with up to 15% of patients with cancer now experiencing VTE. Oncology nurses are ideally situated to assist in the identification of patients at risk for thrombotic events. This activity will discuss strategies ...
|
|
Management of Venous Thromboembolism in Hospitalized Patients With Cancer
STATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer, and hospitalized cancer patients are at an increased risk for both first-time and recurrent VTE. The National Comprehensive Cancer Network (NCCN) recommends VTE prophylaxis for all hospitalized cancer patients. Therefore, it is crucial for oncology nurses to be aware of risk...
|
|
Management of Venous Thromboembolism in Hospitalized Patients With Cancer
TATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer, and hospitalized cancer patients are at an increased risk for both first-time and recurrent VTE. The National Comprehensive Cancer Network (NCCN) recommends VTE prophylaxis for all hospitalized cancer patients. Therefore, it is crucial for oncology nurses to be aware of risk fa...
|
|
Nursing Management of Cancer Treatment Induced Cardiotoxicity
STATEMENT OF NEED
Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in some cases, years after the therapy has been discontinued. Often the cardiotoxicity presents in subtle ways, and a lack of awareness results in high ...
|
|
Nursing Management of Oral Mucositis
STATEMENT OF NEED
Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). Patients with OM may experience moderate-to-severe pain, difficulty speaking, difficulty eating and drinking, and ulcerations characterized by submucosal hemorrhaging and infection (Bolton, 2021). Due to th...
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among canc...
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to scree...
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky &...
|
|
Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care
STATEMENT OF NEED
Precision medicine is a cutting-edge approach that incorporates an individual’s genomic, environmental, and lifestyle information to deliver personalized healthcare. Genetic testing and counseling are crucial components of precision medicine, enabling clinicians to deliver the right care to the right patient at the right time (Turbitt et al, 2023). However, genetic testing...
|
|
Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts affected individuals’ quality of life. The most common subtype is plaque psoriasis, characterized by erythematous to violaceous plaques covered with scales. Due to the substantial symptom burden of plaque psoriasis and challenges surrounding medication tolerability and adherence, innovative treatment ...
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among canc...
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among canc...
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among canc...
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel th...
|
|
Podcast: Multidisciplinary Task Force: Diagnosis and Management of Dedifferentiated Liposarcoma
STATEMENT OF NEED
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). C...
|
|
Podcast: Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hem...
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. ...
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are...
|
|
Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hem...
|
|
Prevention of Medical Errors in Nursing Practice
STATEMENT OF NEED
Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global problem; they affect as many as 20% of patients in primary and outpatient care and complicate a patient’s primary condition for which they ne...
|
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations gr...
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. ...
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are...
|
|